Editorial Videos

In this part of their Pharmaceutical Executive video interview, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss how UpScriptHealth is working to increase access to legitimate weight loss medications, especially for those in underserved communities.

In this part of their Pharmaceutical Executive video interview, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, explain how their company guarantees the authenticity of the medications it dispenses, and the measures are in place to prevent counterfeit drugs from entering their supply chain.

In this part of their Pharmaceutical Executive video interview, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, comment on how Eli Lilly's recent announcement to sell Zepbound DTC will impact the counterfeit weight loss drug issue.

In this part of their Pharmaceutical Executive video interview, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, and the potential health risks associated with them.

In an interview with Pharm Exec Associate Editor Don Tracy, Joseph Mikhael, MD, chief medical officer, IMF, discusses challenges of access and advancement of myeloma therapies.

In an interview with Pharm Exec Associate Editor Don Tracy, Joseph Mikhael, chief medical officer, IMF, offers a glimpse at multiple initiatives that the IMF is working towards to improve myeloma treatment globally.

In an interview with Pharm Exec Associate Editor Don Tracy, Joseph Mikhael, MD, chief medical officer, IMF, explains the goals of the inaugural Iceland Cycling Expedition.

In an interview with Pharm Exec Associate Editor Don Tracy, Carlos Doti, VP, Head of Medical Affairs, US Oncology Business Unit, AstraZeneca, discusses a number of oncology targets in the works at AstraZeneca.

In an interview with Pharm Exec Associate Editor Don Tracy, Carlos Doti, VP, Head of Medical Affairs, US Oncology Business Unit, AstraZeneca, talks PARP inhibitors in cancer treatment and the history of Lynparza.

In this part of his Pharmaceutical Executive video interview, Brian Hillberdink, EVP, LEO Pharma and President of LEO Pharma's US affiliate, talks about how they balance the need for profitability with the mission of providing treatments for rare diseases.

In this part of his Pharmaceutical Executive video interview, Brian Hillberdink, EVP, LEO Pharma and President of LEO Pharma's US affiliate, discusses how is LEO Pharma positioning itself to capitalize on the unmet needs, patient centric initiatives, and more.

In an interview with Pharm Exec Associate Editor Don Tracy, Carlos Doti, VP, head of medical affairs, US oncology business unit, AstraZeneca, provides an update on current research efforts for Lynparza and discusses its impact on cancer patients over the past decade.

In this part of her Pharmaceutical Executive video interview, Charlotte Owens, MD, FACOG, Head of Medical Affairs and Outcomes Research at Organon, discusses how she's using her in-practice experience as an OB-GYN to inform Organon's strategic approach to addressing maternal health challenges.

In an interview with Pharm Exec Associate Editor Don Tracy, Carlos Doti, VP, head of medical affairs, US oncology business unit, offers his thoughts on the evolution of Lynparza across indications such as breast, prostate, and pancreatic cancers.

In this part of her Pharmaceutical Executive video interview, Charlotte Owens, MD, FACOG, Head of Medical Affairs and Outcomes Research at Organon, identifies Organon's efforts to invest in research, education, and its pipeline to focus on critical areas of need in maternal health.

In this part of her Pharmaceutical Executive video interview, Charlotte Owens, MD, FACOG, Head of Medical Affairs and Outcomes Research at Organon, talks about the most critical to close the gaps in R&D for maternal health solutions and how feasible the fixes are.

In this part of her Pharmaceutical Executive video interview, Charlotte Owens, MD, FACOG, Head of Medical Affairs and Outcomes Research at Organon, discusses the societal implications of maternal health issues both short and long term.

In this part of his Pharmaceutical Executive video interview, Joshua M. Cohen, MD, MPH, FAHS, Chief Medical Officer, Braeburn discusses how the findings from this study contribute to addressing treatment gaps and improving patient outcomes for those struggling with fentanyl dependence, ensuring broader patient access to BRIXADI®, and more.

In this part of his Pharmaceutical Executive video interview, Joshua M. Cohen, MD, MPH, FAHS, Chief Medical Officer, Braeburn discusses data from the Phase III trial recently published in JAMA and how confident they are in the generalizability of these findings to a real-world treatment setting.

In this part of his Pharmaceutical Executive video interview, Fabrice Chouraqui, CEO of Cellarity, discusses some other potential areas where Cellarity's approach could be particularly impactful.

In this part of his Pharmaceutical Executive video interview, Fabrice Chouraqui, CEO of Cellarity, speaks about the broader implications of Cellarity's approach for the drug discovery field.

In this part of his Pharmaceutical Executive video interview, Fabrice Chouraqui, CEO of Cellarity, discusses how their AI/ML approach differs and the advantages it offers in terms of uncovering novel treatment opportunities.

In an interview with Pharm Exec Associate Editor Don Tracy, Kathy Lee-Sepsick, Founder, CEO, Femasys, discusses results of the Femaseed pivotal trial, Fembloc birth control, and how the outcome of the 2024 United States presidential election could impact women's health.

In an interview with Pharm Exec Associate Editor Don Tracy, Kathy Lee-Sepsick, Founder, CEO, Femasys, offers a description of how Femaseed works to support women who struggle with infertility.

In an interview with Pharm Exec Associate Editor Don Tracy, Leonard Mazur, Co-founder, CEO, Citius Pharmaceuticals, offers an update on the recently accepted Biologics License Application for Lymphir by the FDA and other candidates currently in the Citius pipeline.

In an interview with Pharm Exec Associated Editor Don Tracy, Leonard Mazur, Co-Founder, CEO, Citius Pharmaceuticals, discusses recent topline results from the pivotal Phase III Clinical Trial of Mino-Lok, which works to salvage catheters infections.

In this part of his Pharmaceutical Executive video interview, Michael Abrams, Managing Partner, Numerof & Associates, identifies the main factors contributing to closures of pharmacies big and small and some potential long-term consequences for public health if they continue.

In this part of his Pharmaceutical Executive video interview, Michael Abrams, Managing Partner, Numerof & Associates, speaks about the specific challenges that pharmacy deserts becoming a national issue presents for rural and underserved areas. Plus a discussion of which alternative solutions can help ensure continued access to medications for all.